Literature DB >> 8849001

Autosomal dominant "Opitz" GBBB syndrome due to a 22q11.2 deletion.

D M McDonald-McGinn1, D A Driscoll, L Bason, K Christensen, D Lynch, K Sullivan, D Canning, W Zavod, N Quinn, J Rome.   

Abstract

We report on a family with autosomal dominant paternally inherited "Opitz" GBBB syndrome and an additional case with findings which have been reported in that syndrome. In each case the propositus presented with a vascular ring. Since a vascular ring may be a sign of a 22q11.2 deletion [Zacki et al., 1995], FISH (fluorescence in situ hybridization) studies were performed. These studies demonstrated a 22q11.2 deletion in the 3 affected individuals. Review of Opitz GBBB syndrome and the 22q11.2 microdeletion syndrome demonstrates significant overlap of manifestations including both facial characteristics and structural anomalies. Based on the phenotypic overlap and the presence of a 22q11.2 deletion in our patients with Opitz GBBB syndrome and the presence of a deletion in a patient with lung hypoplasia, absent pulmonary artery, and long segment tracheomalacia, we propose that, in some cases, the Opitz GBBB syndrome may be due to a 22q11.2 deletion. This enlarges the list of "syndromes" associated with the 22q11.2 deletion, which presently includes most patients with DiGeorge, velocardiofacial, and conotruncal anomaly face syndrome.

Entities:  

Mesh:

Year:  1995        PMID: 8849001     DOI: 10.1002/ajmg.1320590122

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  35 in total

1.  Corpus callosum morphology and ventricular size in chromosome 22q11.2 deletion syndrome.

Authors:  Alexei M C Machado; Tony J Simon; Vy Nguyen; Donna M McDonald-McGinn; Elaine H Zackai; James C Gee
Journal:  Brain Res       Date:  2006-12-13       Impact factor: 3.252

2.  Identification of a novel transcript disrupted by a balanced translocation associated with DiGeorge syndrome.

Authors:  H F Sutherland; R Wadey; J M McKie; C Taylor; U Atif; K A Johnstone; S Halford; U J Kim; J Goodship; A Baldini; P J Scambler
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

3.  Symptomatic anal anomalies in chromosome 22q11 deletion syndrome: a report of three patients.

Authors:  Mudaffer Al-Mudaffer; Prem Puri; William Reardon
Journal:  Pediatr Surg Int       Date:  2006-02-17       Impact factor: 1.827

Review 4.  A new account of the neurocognitive foundations of impairments in space, time and number processing in children with chromosome 22q11.2 deletion syndrome.

Authors:  Tony J Simon
Journal:  Dev Disabil Res Rev       Date:  2008

5.  Anal anomalies: an uncommon feature of velocardiofacial (Shprintzen) syndrome?

Authors:  S Worthington; A Colley; K Fagan; K Dai; A H Lipson
Journal:  J Med Genet       Date:  1997-01       Impact factor: 6.318

6.  Practical guidelines for managing patients with 22q11.2 deletion syndrome.

Authors:  Anne S Bassett; Donna M McDonald-McGinn; Koen Devriendt; Maria Cristina Digilio; Paula Goldenberg; Alex Habel; Bruno Marino; Solveig Oskarsdottir; Nicole Philip; Kathleen Sullivan; Ann Swillen; Jacob Vorstman
Journal:  J Pediatr       Date:  2011-05-12       Impact factor: 4.406

7.  Detection of an atypical 22q11 deletion that has no overlap with the DiGeorge syndrome critical region.

Authors:  H O'Donnell; C McKeown; C Gould; B Morrow; P Scambler
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

Review 8.  Genetics and signaling mechanisms of orofacial clefts.

Authors:  Kurt Reynolds; Shuwen Zhang; Bo Sun; Michael A Garland; Yu Ji; Chengji J Zhou
Journal:  Birth Defects Res       Date:  2020-07-15       Impact factor: 2.344

9.  The 22q11.2 deletion in African-American patients: an underdiagnosed population?

Authors:  Donna M McDonald-McGinn; Nancy Minugh-Purvis; Richard E Kirschner; Abbas Jawad; Melissa K Tonnesen; Jason R Catanzaro; Elizabeth Goldmuntz; Deborah Driscoll; Don Larossa; Beverly S Emanuel; Elaine H Zackai
Journal:  Am J Med Genet A       Date:  2005-04-30       Impact factor: 2.802

10.  Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke.

Authors:  Laure Allard; Natacha Turck; Pierre R Burkhard; Nadia Walter; Anna Rosell; Marianne Gex-Fabry; Denis F Hochstrasser; Joan Montaner; Jean-Charles Sanchez
Journal:  Biomark Insights       Date:  2007-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.